Voices
Menin Inhibitor
Talha Badar/X

Talha Badar: Achieving Effective AML Cell Death with p53 Restoration and MDM2/BCL2 or XPO1 Inhibitors

Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared a post on X about a recent article by Bing Z. Carter et al. published in Blood:

“Restoring p53 wild-type conformation in TP53-Y220C–mutant acute myeloid leukemia.

More effective AML cell death occurred when given in combination with MDM2/BCL2 or XPO1 inhibitors.”

Title: Restoring p53 wild-type conformation in TP53-Y220C–mutant acute myeloid leukemia

Authors: Bing Z. Carter, Po Yee Mak, Edward Ayoub, Xiaogang Wu, Baozhen Ke, Yuki Nishida, Andrew Futreal, Lauren B. Ostermann, Andrea D. Bedoy, Steffen Boettcher, Courtney D. DiNardo, Anna Puzio-Kuter, Masha V. Poyurovsky, Arnold Levine, Michael Andreeff

Read the Full Article on Blood

Talha Badar: Achieving Effective AML Cell Death with p53 Restoration and MDM2/BCL2 or XPO1 Inhibitors

More posts featuring Talha Badar.

 

AML Andrea D Bedoy Andrew Futreal Anna Puzio-Kuter Arnold Levine Baozhen Ke Bing Z. Carter cancer Courtney D. DiNardo Edward Ayoub Lauren B Ostermann Masha V Poyurovsky Michael Andreeff OncoDaily Oncology Po Yee Mak Steffen Boettcher Talha Badar Xiaogang Wu Yuki Nishida